Free Newsletter
Texas touts $3B plan for cancer research
Taking a page from the California playbook on biomedical research, Texas has announced plans to invest $3 billion in cancer research over the next 10 years. Not surprisingly, the project draws on some of the state's highest-profile research organizations. The state is already home to the Lance Armstrong Foundation, named after testicular cancer survivor and high-profile athlete Lance Armstrong, the Susan G. Komen breast cancer foundation and the University of Texas M.D. Anderson Cancer Center. Under the new project, the three will work together along with universities, medical schools and for-profit companies. Gov. Rick Perry didn't hide the fact that the project has a commercial as well as a humanitarian purpose, noting that the new fund would draw high-tech companies and high salaries to the state. To date, it's not clear where the funds will actually come from--though one proposal involves borrowing against bonds to produce $300 million a year--but two of the state's Republican lawmakers have at least committed to sponsor a bill creating the fund. A number of states have jumped on the bandwagon to provide funds for research. New York is examining a proposal from its new governor to offer $2 billion in funding, half of which would go to stem cell research.
- read the Washington Post report on the initiative
Related Articles:
Study finds women shortchanged on chemotherapy. Report
Mayo Clinic signs cancer research deal. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: